Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

ClinicalTrials.gov ID: NCT01590459

Public ClinicalTrials.gov record NCT01590459. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is designed to evaluate the safety and efficacy of VX-509, an oral JAK3 inhibitor, for treatment of subjects with active RA who have had an inadequate response to Methotrexate.

Study identification

NCT ID
NCT01590459
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
359 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2012
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014
Last update posted
Nov 19, 2015

2012 – 2014

United States locations

U.S. sites
31
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Vertex Investigational Site Birmingham Alabama
Vertex Investigational Site Huntsville Alabama
Vertex Investigational Site Long Beach California
Vertex Investigational Site Tustin California
Vertex Investigational Site Boca Raton Florida
Vertex Investigational Site Daytona Beach Florida
Vertex Investigational Site New Port Richey Florida
Vertex Investigational Site North Miami Beach Florida
Vertex Investigational Site Ocala Florida
Vertex Investigational Site Tampa Florida
Vertex Investigational Site Springfield Illinois
Vertex Investigational Site Wichita Kansas
Vertex Investigational Site Kalamazoo Michigan
Vertex Investigational Site St Louis Missouri
Vertex Investigational Site Omaha Nebraska
Vertex Investigational Site Las Vegas Nevada
Vertex Investigational Site Clifton New Jersey
Vertex Investigational Site Freehold New Jersey
Vertex Investigational Site Brooklyn New York
Vertex Investigational Site Charlotte North Carolina
Vertex Investigational Site Durham North Carolina
Vertex Investigational Site Hickory North Carolina
Vertex Investigational Site Oklahoma City Oklahoma
Vertex Investigational Site Bethlehem Pennsylvania
Vertex Investigational Site Duncansville Pennsylvania
Vertex Investigational Site Jackson Tennessee
Vertex Investigational Site Austin Texas
Vertex Investigational Site Houston Texas
Vertex Investigational Site Mesquite Texas
Vertex Investigational Site San Antonio Texas
Vertex Investigational Site Clarksburg West Virginia

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 63 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01590459, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 19, 2015 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01590459 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →